Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Kallelse till årsstämma i Nilar International AB (publ) / Notice of annual general meeting in Nilar International AB (publ)

Aktieägarna i Nilar International AB, org. nr 556600-2977, ("Bolaget") kallas härmed till årsstämma tisdagen den 30 juni 2020 kl. 16.00 i Baker & McKenzie advokatbyrås lokaler på Vasagatan 7 i Stockholm. The shareholders of Nilar International AB, reg. no. 556600-2977, (the "Company"), are hereby convened to the annual general meeting to be held on Tuesday 30 June 2020, at 16.00 at Baker & McKenzie’s premises on Vasagatan 7 in Stockholm, Sweden.

Oncoinvent Announces Dosing of First Patient with Radspherin[® ]in Phase 1 Clinical Trial

Radiopharmaceutical company starts first-in-human trial in colorectal patients suffering from peritoneal carcinomatosisOncoinvent AS, a clinical stage radiopharmaceutical company developing novel radioisotope-based therapies to provide new therapeutic options for cancer patients, today announced that the first patient has been dosed in the phase 1, first-in-human clinical trial of it’s lead candidate compound Radspherin[®]. “Radspherin[®] represents a promising new approach for treating patients with metastates to the peritoneal cavity from colorectal cancer that may potentially provide

BERGENBIO CONFIRMS FIRST COVID19 PATIENT DOSED WITH BEMCENTINIB IN ACCORD TRIAL

Bergen, Norway – 02 June 2020: BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, today announces that dosing has commenced in the UK Government-backed Phase II clinical trial assessing bemcentinib in hospitalised COVID-19 patients. Bemcentinib was selected as the first candidate to be tested as part of the ACcelerating COVID-19 Research & Development platform (ACCORD) study, launched by the Department of Health and Social Care (DHSC) and UK Research and Innovation (UKRI) on 28[th] April

Seadrill Limited (SDRL) - First Quarter 2020 Results

Material impairments on assets and investments and a focus on restructuringHighlights ·Revenue down 19% at $321 million with lower proportion of reimbursable revenues ·Technical utilization of 95% and economic utilization of 93% ·Operating Loss of $1,284 million after making material asset impairments ·Adjusted EBITDA of $55 million, representing 17.1% margin ·Net loss attributable to shareholder of $1,564 million equivalent to net loss per share of $15.59 ·During the quarter we added $77 million in backlog, maintaining a total backlog figure of $2.

Sustainable production methods and traceability of materials for battery manufacturing

Press release 2.6.2020  The success of electric cars on the markets may be determined by production methods and origin information of battery materials in the future. VTT and Geological Survey of Finland GTK launched a three-year project with their industrial partners to promote the sustainable production methods and traceability of battery materials. A promising starting point for tracing the origin is offered by the fingerprint conserved in the metals, which may directly tell where the metals were mined.When examining transport emissions, electric cars using renewable electricity

Camurus announces submission of request for final approval of Brixadi™ for the treatment of opioid use disorder in the US

Lund, Sweden — 1 June 2020 — Camurus AB (NASDAQ STO: CAMX) today announces that the company’s US partner Braeburn has submitted a request for final approval of Brixadi™ (buprenorphine) weekly and monthly extended release injection for the treatment of opioid use disorder to the US Food and Drug Administration (FDA). On 21 December 2018, Brixadi (the US trade name for Buvidal[®]) was tentatively approved by the FDA, having met all regulatory requirements regarding efficacy, safety and quality. However, Brixadi was not eligible for marketing in the US because of an exclusivity period

SAGAX COMPLETES A DIRECTED ISSUE OF CLASS D COMMON SHARES, RAISING PROCEEDS OF SEK 513 MILLION

The board of directors in AB Sagax (publ) (”Sagax” or the ”Company”) has, based on the authorization granted by the annual general meeting on 6 May 2020, resolved on a directed issue of 18,000,000 class D common shares (the “Share issue”). Due to strong demand, the Share issue has been upsized with two million shares from what was previously communicated (refer to press release no.15). Through the Share issue, Sagax receives SEK 513m before transaction costs. The price of SEK 28,50 per share has been determined in an accelerated book building process and corresponds to a discount of 2,51

SDRL – Seadrill Limited Intention to Delist from the New York Stock Exchange (NYSE)

Hamilton, Bermuda, June 1, 2020 – Seadrill Limited ("Seadrill" or the "Company") today announces its intention to delist from the New York Stock Exchange (NYSE).  On March 26, 2020, Seadrill received written notice from the NYSE that it was not in compliance with the NYSE continued listing standard with respect to the minimum average share price required, because the average closing price of its common shares had fallen below $1.00 per share over a period of 30 consecutive trading days. On April 8, 2020, the Company provided the required notice to the NYSE, in which the Company stated

Keliber - EIA program of the Päiväneva mine and concentrator site submitted to the authorities

Keliber has submitted the program for environmental impact assessment (“EIA”) of the Päiväneva mine and concentrator site to the authorities. The program covers relevant environmental and social factors to be further investigated. The assessments will provide guidance for the industrial planning of the area. For further information please see Keliber’s press release today: https://www.keliber.fi/en/news/news-releases-and-publications/B8F144816971C87F/ Nordic Mining ASA holds an investment of 16.3% in Keliber.Oslo, 1 June 2020Nordic Mining ASANordic Mining ASA (www.nordicmining.

Subscription period postponed for the rights issue. Other conditions remain unchanged

SpectraCure AB (publ) postpones the subscription period for the rights issue which was announced on 5 May 2020. The new subscription period is between Friday, 5 June 2020 and Tuesday, 23 June 2020 inclusive. All other terms and conditions of the rights issue remain unchanged. The Board of Directors of SpectraCure AB (publ) has resolved to postpone the subscription period for the rights issue which was announced on 5 May 2020. The new subscription period is between Friday, 5 June 2020 and Tuesday, 23 June 2020 inclusive. The reason for this decision is that the registration of the

Sandvik completes the acquisition of QCT’s division for cutting tools

Sandvik has completed the previously announced acquisition of the cutting tools division of QUIMMCO CENTRO TECNOLÓGICO (QCT), a privately owned Mexican company offering integral machining solutions. In 2019, QCT’s cutting tools division generated revenues of about 90 million SEK with 130 employees. The deal has a limited impact on earnings per share from the start. QCT’s cutting tool division will be part of Seco Tools, a division within Sandvik Machining Solutions.   Stockholm, 1 June 2020  Sandvik AB For further information, contact Anna Vilogorac, Investor Relations,

The Nomination Committee's proposal for the Board of Directors and adjusted proposal for the Annual General Meeting 2020

In the notice of the Annual General Meeting of Brighter AB (publ) published on May 13, 2020, the Nomination Committee announced that it would get back with a proposal for the election of Board members. The Nomination Committee's proposal is presented below. The shareholder Recall Capital Nordic AB has also requested an adjustment of the proposed incentive program for the Board of Directors, which is described in full on Brighter's website https://brighter.se/. The Nomination Committee's proposalsThe Nomination Committee proposes that Truls Sjöstedt, Jan Stålemark, Emanuel Lipschütz and

MHI Vestas Offshore Wind A/S has signed a conditional agreement for the delivery of turbines comprising 1,140 MW for an offshore project in the UK

Vestas Wind Systems A/S, Aarhus, 01 June 2020Company announcement No. 22/2020   MHI Vestas Offshore Wind A/S has signed a conditional agreement for the delivery of turbines comprising 1,140 MW for an offshore project in the UK   MHI Vestas Offshore Wind A/S has signed a conditional agreement for the Seagreen offshore project in the UK. If and when the project translates into a firm order, Vestas Wind Systems A/S will disclose a company announcement about this. The project is to be delivered by MHI Vestas Offshore Wind and will not enter into the order backlog of Vestas Wind

SAGAX EXPLORES THE CONDITIONS FOR A DIRECTED ISSUE OF CLASS D COMMON SHARES

AB Sagax (publ) (”Sagax” or the ”Company”) has appointed ABG Sundal Collier to explore the conditions for a directed issue of up to approximately 16 million class D common shares (the “Share issue”) to Swedish and international professional investors in the Nordics and certain other jurisdictions through an accelerated book building process. The potential Share issue is executed in accordance with the authorization granted by the annual general meeting on 6 May 2020. The purpose of the Share issue is to strengthen the Company’s credit profile and financial flexibility for real estate

Adapteo Corporation: SHARE REPURCHASE 1.6.2020

Adapteo Corporation  ANNOUNCEMENT  1.6.2020 Adapteo Corporation: SHARE REPURCHASE 1.6.2020 In the Stockholm Stock Exchange Trade date           1.6.2020Bourse trade         BuyShare                  ADAPTAmount             10 000 SharesAverage price/ share    76,6847 SEKTotal cost            766 847,00 SEK Adapteo Corporation now holds a total of 28 693 sharesincluding the shares repurchased on 1.6.2020 On behalf of Adapteo Corporation Nordea Bank Oyj

#20-193 Delisting of certain Derivatives from NGM

Certain derivatives will be delisted from NGM.For more details see attached files. For further information concerning this NGM notice please contact: Listing department on +46 8 566 390 20 or at listings@ngm.se Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for companies

#20-192 Listing of Derivatives at NGM

Information about various derivatives that will be listed at NGM.For more details see attached file. For further information concerning this NGM notice please contact: Listing on +46 8 566 390 20 or at listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for

Publication of a Prospectus

Regulatory Announcement Royal Bank of CanadaJune 1, 2020 Publication of Prospectus Not for release, publication or distribution, directly or indirectly, in or into the United States. The following prospectus has been approved by the Financial Conduct Authority and is available for viewing: 5[th] Supplementary Notes Base Prospectus dated June 1, 2020 relating to the Programme for the Issuance of Securities of Royal Bank of Canada. The 5[th] Supplementary Notes Base Prospectus, together with the document incorporated by reference therein, have been submitted to the

Niklas Carlén Appointed New CFO at Stille

Stille AB (publ) informs about a change in group management and the appointment of a new CFO.Stille has appointed Niklas Carlén as the new CFO for the company and a member of the group management. Niklas Carlén has a Masters Degree of Science in Business Administration and Economics from Örebro University. He has for the past 15 years worked as a CFO at Calix, Swecon and TOOLS Sverige, most recently as the CFO at Eskilstuna Strängnäs Energi och Miljö. I am very pleased with welcoming Niklas to Stille and as part of the group management. Niklas is highly competent with 15 years in the

Össur hf: Össur closes acquisition of College Park Industries

1 June 2020 Össur closes acquisition of College Park Industries As previously announced, Össur signed an agreement to acquire College Park Industries in July 2019 and the acquisition was approved by the Federal Trade Commission (FTC) in April 2020. The transaction has now been officially closed and College Park is now wholly owned by Össur. As part of the transaction, the Espire Elbow line has been acquired by UK-based Steeper Group. College Park’s pro-forma FY2019 sales excluding the Espire sales amount to approximately USD 20 million. College Park is a global provider of

Fellow Finance platform facilitated 8,8 million euros of loans in May

FELLOW FINANCE PLC PRESS RELEASE 1.6.2020 AT 5:00 PMIn May, Fellow Finance investors funded business and peer-to-peer loans worth of 8,8M€. Cumulative loan volume grew over 621 million euros and the total number of investors grew to 16 103. Check the real-time peer-to-peer lending statistics on our website: www.fellowfinance.com/for-investor/statistics. The performance of business and consumer loans, intermediated by Fellow Finance, during the COVID-19 pandemic can be followed on the company's website: https://www.fellowfinance.com/for-investor/statistics. The return index takes into

Total Voting Rights

1 June 2020 15:00 BST     Transparency Directive Voting Rights and Capital The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 31 May 2020 the issued share capital of AstraZeneca PLC with voting rights is 1,312,261,399 ordinary shares of US$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,312,261,399.   The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by

There are no items matching the current filter
There are no more items matching the current filter
Back to top